Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen-activated protein kinase kinase signaling pathways

Molecular Medicine Reports

Volumn 12, Issue 5, 2015, Pages 6745-6751

  Hu, Shan ^a   Huang, Liming ^a   Meng, Liwei ^a   Sun, He ^a   Zhang, Wei ^a   Xu, Yingchun ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Akt; Apoptosis; Breast cancer; Isorhamnetin; Mitogen activated protein kinase kinase

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISORHAMNETIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN BCL 2; 3-METHYLQUERCETIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; PROTEIN KINASE B; QUERCETIN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL COUNTING; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC50; MCF 7 CELL LINE; MOLECULARLY TARGETED THERAPY; MORTALITY; PROTEIN EXPRESSION; RADIOIMMUNOPRECIPITATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; FEMALE; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; QUERCETIN;

EID: 84943620855     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4269     Document Type: Article

References (32)

1. American Cancer Society. Cancer Facts & Figures 2013. American Cancer Society, Atlanta, 2013.
2. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L and He J: Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res 25: 10-21, 2013.
3. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 49: 1374-1403, 2013.
4. Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer 13: 714-726, 2013.
5. Massarweh S and Schiff R: Resistance to endocrine therapy in breast cancer: Exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 13 (Suppl 1): S15-S24, 2006.
6. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743, 2006.
7. Guarneri V and Conte P: Metastatic breast cancer: Therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 14: 645-656, 2009.
8. Fedele P, Calvani N, Marino A, Orlando L, Schiavone P, Quaranta A and Cinieri S: Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: Where are we now and where are we going? Crit Rev Oncol Hematol 84: 243-251, 2012.
9. Miller TW, Balko JM and Arteaga CL: Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29: 4452-4461, 2011.
10. Perez-Tenorio G and Stal O; Southeast Sweden Breast Cancer Group: Activation of Akt/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86: 540-545, 2002.
11. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA and Hidalgo M: Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10: 8059-8067, 2004.
12. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A and Bartlett JM: Akt activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207: 139-146, 2005.
13. Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H and Maehara Y: Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 13: 137-144, 2006.
14. Donovan JC, Milic A and Slingerland JM: Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 276: 40888-40895, 2001.
15. Jin W, Wu L, Liang K, Liu B, Lu Y and Fan Z: Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 89: 185-191, 2003.
16. Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G and Menard S: The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 207: 420-427, 2006.
17. Yao H, Xu W, Shi X and Zhang Z: Dietary flavonoids as cancer prevention agents. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 29: 1-31, 2011.
18. Asensi M, Ortega A, Mena S, Feddi F and Estrela JM: Natural polyphenols in cancer therapy. Crit Rev Clin Lab Sci 48: 197-216, 2011.
19. Cushnie TP and Lamb AJ: Recent advances in understanding the antibacterial properties of flavonoids. Int J Antimicrob Agents 38: 99-107, 2011.
20. Gupta SC, Kim JH, Prasad S and Aggarwal BB: Regulation of survival, proliferation, invasion, angiogenesis and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29: 405-434, 2010.
21. Ma G, Yang C, Qu Y, Wei H, Zhang T and Zhang N: The flavonoid component isorhamnetin in vitro inhibits proliferation and induces apoptosis in Eca-109 cells. Chem Biol Interact 167: 153-160, 2007.
22. Suomela JP, Ahotupa M, Yang B, Vasankari T and Kallio H: Absorption of flavonols derived from sea buckthorn (Hippophae rhamnoides L.) and their effect on emerging risk factors for cardiovascular disease in humans. J Agric Food Chem 54: 7364-7369, 2006.
23. Shi C, Fan LY, Cai Z, Liu YY and Yang CL: Cellular stress response in Eca-109 cells inhibits apoptosis during early exposure to isorhamnetin. Neoplasma 59: 361-369, 2012.
24. Ramachandran L, Manu KA, Shanmugam MK, Li F, Siveen KS, Vali S, Kapoor S, Abbasi T, Surana R, Smoot DT, et al: Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor γ activation pathway in gastric cancer. J Biol Chem 287: 38028-38040, 2012.
25. Boubaker J, Ben Sghaier M, Skandrani I, Ghedira K and Chekir-Ghedira L: Isorhamnetin 3-O-robinobioside from Nitraria retusa leaves enhance antioxidant and antigenotoxic activity in human chronic myelogenous leukemia cell line K562. BMC Complement Altern Med 12: 135, 2012.
26. Boubaker J, Bhouri W, Ben Sghaier M, Ghedira K, Dijoux Franca MG and Chekir-Ghedira L: Ethyl acetate extract and its major constituent, isorhamnetin 3-O-rutinoside, from Nitraria retusa leaves, promote apoptosis of human myelogenous erythroleukaemia cells. Cell Prolif 44: 453-461, 2011.
27. Kim JE, Lee DE, Lee KW, Son JE, Seo SK, Li J, Jung SK, Heo YS, Mottamal M, Bode AM, et al: Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K. Cancer Prev Res (Phila) 4: 582-591, 2011.
28. Jaramillo S, Lopez S, Varela LM, Rodriguez-Arcos R, Jimenez A, Abia R, Guillen R and Muriana FJ: The flavonol isorhamnetin exhibits cytotoxic effects on human colon cancer cells. J Agric Food Chem 58: 10869-10875, 2010.
29. Lee HJ, Lee HJ, Lee EO, Ko SG, Bae HS, Kim CH, Ahn KS, Lu J and Kim SH: Mitochondria-cytochrome C-caspase-9 cascade mediates isorhamnetin-induced apoptosis. Cancer Lett 270: 342-353, 2008.
30. Li C, Yang X, Chen C, Cai S and Hu J: Isorhamnetin suppresses colon cancer cell growth through the PI3K-Akt-m TOR pathway. Mol Med Rep 9: 935-940, 2014.
31. Di Carlo G, Mascolo N, Izzo AA and Capasso F: Flavonoids: Old and new aspects of a class of natural therapeutic drugs. Life Sci 65: 337-353, 1999.
32. Saud SM, Young MR, Jones-Hall YL, Ileva L, Evbuomwan MO, Wise J, Colburn NH, Kim YS and Bobe G: Chemopreventive activity of plant flavonoid isorhamnetin in colorectal cancer is mediated by oncogenic Src and-catenin. Cancer Res 73: 5473-5484, 2013.